Creative Planning
JANX icon

Creative Planning’s Janux Therapeutics JANX Stock Holding History

Creative Planning’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$679K Buy
44,232
+9,024
+26% +$131K ﹤0.01% 2949
2026
Q1 		$489K Buy
+35,208
New +$483K ﹤0.01% 3048
2025
Q1 		– Sell
-65
Closed -$3.48K – 3600
2024
Q4 		$3.48K Buy
+65
New +$3.44K ﹤0.01% 3428

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Creative Planning's JANX Position: Q2 2026 in Review

Creative Planning increased its Janux Therapeutics (JANX) stake by 26% in Q2 2026, buying an estimated $131K and bringing the position to 44,232 shares worth $679K. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

Creative Planning first reported a position in JANX in Q4 2024 and has held it in 3 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Creative Planning held 44,232 shares of Janux Therapeutics worth $679K as of Q2 2026.
  • Creative Planning bought 9,024 Janux Therapeutics shares in Q2 2026, an estimated $131K.
  • Janux Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2949 holding.
  • Creative Planning first reported a position in Janux Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.